Regenxbio Company Profile (NASDAQ:RGNX)

About Regenxbio

Regenxbio logoREGENXBIO Inc. is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors). Its NAV Technology Platform is applied in the development of approximately 30 product candidates for a range of diseases, including over five internally developed product candidates and approximately 20 partnered product candidates developed by its NAV Technology Licensees. Its therapeutic programs include RGX-501 for Homozygous familial hypercholesterolemia (HoFH); RGX-111 for Mucopolysaccharidosis Type I (MPS I); RGX-121 for Mucopolysaccharidosis Type II (MPS II); RGX-314 for Wet age related macular degeneration (wet AMD), and RGX-321 for X-linked retinitis pigmentosa (XLRP).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: RGNX
  • CUSIP:
Key Metrics:
  • Previous Close: $13.88
  • 50 Day Moving Average: $13.11
  • 200 Day Moving Average: $11.04
  • 52-Week Range: $7.07 - $25.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.97
  • P/E Growth: 0.00
  • Market Cap: $367.33M
  • Outstanding Shares: 26,465,000
Profitability:
  • Net Margins: -451.73%
  • Return on Equity: -17.89%
  • Return on Assets: -17.34%
Debt:
  • Current Ratio: 10.71%
  • Quick Ratio: 10.71%
Additional Links:
Companies Related to Regenxbio:

Analyst Ratings

Consensus Ratings for Regenxbio (NASDAQ:RGNX) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $31.25 (125.14% upside)

Analysts' Ratings History for Regenxbio (NASDAQ:RGNX)
Show:
DateFirmActionRatingPrice TargetDetails
8/22/2016Chardan CapitalReiterated RatingBuyView Rating Details
8/18/2016Piper Jaffray Cos.Set Price TargetBuy$25.00View Rating Details
4/8/2016Morgan StanleyBoost Price Target$34.00 -> $36.00View Rating Details
10/12/2015Bank of America Corp.Initiated CoverageBuy$29.00View Rating Details
(Data available from 9/30/2014 forward)

Earnings

Earnings History for Regenxbio (NASDAQ:RGNX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/3/2016        
8/9/2016Q2($0.53)($0.55)ViewListenView Earnings Details
5/5/2016($0.40)($0.41)ViewN/AView Earnings Details
3/3/2016Q415($0.34)($0.20)$1.23 million$4.40 millionViewN/AView Earnings Details
11/5/2015Q315($0.35)($1.52)$1.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Regenxbio (NASDAQ:RGNX)
Current Year EPS Consensus Estimate: $-2.37 EPS
Next Year EPS Consensus Estimate: $-2.79 EPS

Dividends

Dividend History for Regenxbio (NASDAQ:RGNX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Regenxbio (NASDAQ:RGNX)
Insider Ownership Percentage: 21.00%
Institutional Ownership Percentage: 68.73%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/17/2016Fmr LlcInsiderSell18,300$12.41$227,103.00View SEC Filing  
5/16/2016Fmr LlcInsiderSell16,030$11.65$186,749.50View SEC Filing  
5/12/2016Fmr LlcInsiderSell6,711$10.85$72,814.35View SEC Filing  
5/11/2016Fmr LlcInsiderSell25,132$10.36$260,367.52View SEC Filing  
5/9/2016Fmr LlcInsiderSell10,570$9.94$105,065.80View SEC Filing  
5/4/2016Fmr LlcInsiderSell1,896$10.51$19,926.96View SEC Filing  
5/3/2016Fmr LlcInsiderSell6,046$10.76$65,054.96View SEC Filing  
4/29/2016Fmr LlcInsiderSell4,723$10.80$51,008.40View SEC Filing  
4/28/2016Fmr LlcInsiderSell33,196$11.23$372,791.08View SEC Filing  
4/26/2016Fmr LlcInsiderSell9,188$11.19$102,813.72View SEC Filing  
4/22/2016Fmr LlcInsiderSell20,558$11.30$232,305.40View SEC Filing  
4/20/2016Fmr LlcInsiderSell13,189$11.66$153,783.74View SEC Filing  
4/18/2016Fmr LlcInsiderSell18,900$11.75$222,075.00View SEC Filing  
4/14/2016Fmr LlcInsiderSell27,036$11.46$309,832.56View SEC Filing  
9/22/2015James E FlynnInsiderBuy175,000$22.00$3,850,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Regenxbio (NASDAQ:RGNX)
DateHeadline
4-traders.com logoREGENXBIO : Publishes Data from Ongoing Preclinical Studies of NAV Gene Therapy in Neurodegenerative Diseases (NASDAQ:RGNX)
www.4-traders.com - September 16 at 10:35 AM
streetinsider.com logoRegenxbio (RGNX) Issues Update on NAV Gene Therapy for MPS I, MPS II (NASDAQ:RGNX)
www.streetinsider.com - September 13 at 11:55 AM
finance.yahoo.com logoREGENXBIO Publishes Data from Ongoing Preclinical Studies of NAV® Gene Therapy in Neurodegenerative Diseases (NASDAQ:RGNX)
finance.yahoo.com - September 13 at 11:55 AM
finance.yahoo.com logo7:10 am REGENXBIO publishes data from ongoing preclinical studies of NAV gene therapy in neurodegenerative diseases in the Molecular Genetics & Metabolism Journal (NASDAQ:RGNX)
finance.yahoo.com - September 13 at 11:55 AM
biz.yahoo.com logoREGENXBIO INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:RGNX)
biz.yahoo.com - September 12 at 6:41 PM
finance.yahoo.com logoREGENXBIO to Participate in Global Healthcare Conferences (NASDAQ:RGNX)
finance.yahoo.com - September 7 at 7:09 PM
4-traders.com logoRegenxbio : Daniel Tass Appointed to REGENXBIO Board of Directors (NASDAQ:RGNX)
www.4-traders.com - August 19 at 10:04 AM
publicnow.com logoDaniel Tassé Appointed to REGENXBIO Board of Directors (NASDAQ:RGNX)
www.publicnow.com - August 16 at 10:27 AM
biz.yahoo.com logoREGENXBIO INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits (NASDAQ:RGNX)
biz.yahoo.com - August 16 at 10:27 AM
finance.yahoo.com logoEdited Transcript of RGNX earnings conference call or presentation 9-Aug-16 12:30pm GMT (NASDAQ:RGNX)
finance.yahoo.com - August 10 at 10:14 AM
twst.com logoRegenxbio Inc.: REGENXBIO Reports Second Quarter 2016 Financial Results and Recent Operational Highlights (NASDAQ:RGNX)
www.twst.com - August 9 at 10:18 AM
globenewswire.com logoREGENXBIO Reports Second Quarter 2016 Financial Results and Recent Operational Highlights (NASDAQ:RGNX)
globenewswire.com - August 9 at 10:18 AM
cnbc.com logoRegenxbio reports 2Q loss (NASDAQ:RGNX)
www.cnbc.com - August 9 at 10:18 AM
biz.yahoo.com logoRegenxbio Inc Earnings Call scheduled for 8:30 am ET today (NASDAQ:RGNX)
biz.yahoo.com - August 9 at 10:18 AM
publicnow.com logoDaniel J. Abdun-Nabi Appointed to REGENXBIO Board of Directors (NASDAQ:RGNX)
www.publicnow.com - August 8 at 7:20 PM
publicnow.com logoFDA Grants Rare Pediatric Disease Designation to REGENXBIO's RGX-121 Gene Therapy for the Treatment of Mucopolysaccharidosis Type II (MPS II) (NASDAQ:RGNX)
www.publicnow.com - August 2 at 12:04 PM
biz.yahoo.com logoREGENXBIO INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:RGNX)
biz.yahoo.com - August 2 at 12:04 PM
publicnow.com logoREGENXBIO to Host Conference Call on August 9 to Discuss Second Quarter 2016 Financial Results and Recent Operational Highlights (NASDAQ:RGNX)
www.publicnow.com - August 1 at 6:53 PM
benzinga.com logoCould Regenxbio Shares Have 320% Upside? (NASDAQ:RGNX)
www.benzinga.com - July 8 at 10:00 AM
insidermonkey.com logoThis Protocol Change Means Regenxbio Inc (RGNX) Can Finally Get Started On Its Gene Therapy Trial (NASDAQ:RGNX)
www.insidermonkey.com - July 7 at 2:17 PM
marketexclusive.com logoThis Protocol Change Means Regenxbio Inc (NASDAQ:RGNX) Can Finally Get Started On Its Gene Therapy Trial (NASDAQ:RGNX)
marketexclusive.com - July 6 at 7:25 PM
publicnow.com logoREGENXBIO Provides Update on Lead Gene Therapy Development Programs (NASDAQ:RGNX)
www.publicnow.com - July 5 at 4:21 PM
capitalcube.com logoETF’s with exposure to REGENXBIO, Inc. : June 20, 2016 (NASDAQ:RGNX)
www.capitalcube.com - June 20 at 3:08 PM
biz.yahoo.com logoREGENXBIO INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NASDAQ:RGNX)
biz.yahoo.com - June 1 at 4:31 PM
News IconREGENXBIO Inc. (NASDAQ:RGNX) Broker Price Targets For The Coming Week - Share Trading News (NASDAQ:RGNX)
www.sharetrading.news - May 30 at 2:53 PM
News IconAre Analysts Bearish Regenxbio Inc (NASDAQ:RGNX) After Last Week? - Wall Street Hints and News (NASDAQ:RGNX)
hintsnewsnetwork.com - May 28 at 12:59 PM
News IconEarnings Review and Stock Rundown for Regenxbio Inc (NASDAQ:RGNX) - Wall Street Hints and News (NASDAQ:RGNX)
hintsnewsnetwork.com - May 26 at 1:04 PM
News IconBroker Roundup For REGENXBIO Inc. (NASDAQ:RGNX) - Share Trading News (NASDAQ:RGNX)
www.sharetrading.news - May 25 at 12:35 PM
capitalcube.com logoETF’s with exposure to REGENXBIO, Inc. : May 23, 2016 (NASDAQ:RGNX)
www.capitalcube.com - May 23 at 5:33 PM
News IconNext Weeks Broker Price Targets For REGENXBIO Inc. (NASDAQ:RGNX) - Share Trading News (NASDAQ:RGNX)
www.sharetrading.news - May 23 at 12:34 PM
News IconRegenxbio Incorporated (NASDAQ:RGNX) Short Interest Increased By 2.62% - Wall Street Hints and News (NASDAQ:RGNX)
hintsnewsnetwork.com - May 21 at 12:53 PM
News IconHow Analysts Feel About Regenxbio Inc (NASDAQ:RGNX)? - Wall Street Hints and News (NASDAQ:RGNX)
hintsnewsnetwork.com - May 21 at 12:53 PM
tradecalls.org logoRevenue Update on Regenxbio Inc(NASDAQ:RGNX) - Trade Calls (NASDAQ:RGNX)
www.tradecalls.org - May 21 at 12:53 PM
capitalcube.com logoREGENXBIO, Inc. :RGNX-US: Earnings Analysis: Q1, 2016 By the Numbers (NASDAQ:RGNX)
www.capitalcube.com - May 17 at 3:53 PM
News IconMix Wondering Stocks- Southwest Airlines (NYSE:LUV), Regenxbio (NASDAQ:RGNX), Williams Companies (NYSE ... - Seneca Globe (NASDAQ:RGNX)
www.senecaglobe.com - May 17 at 12:41 PM
streetinsider.com logoRegenxbio (RGNX), Biogen (BIIB) Enter Licensing Agreement for Gene Therapy Treatments - StreetInsider.com (NASDAQ:RGNX)
www.streetinsider.com - May 17 at 12:41 PM
bizjournals.com logoAmgen signs licensing deal for Penn gene therapy technology (NASDAQ:RGNX)
www.bizjournals.com - May 16 at 10:55 AM
publicnow.com logoREGENXBIO and Biogen Enter Exclusive License Agreement for the Development of Gene Therapy Treatments for Rare Genetic Vision Disorders (NASDAQ:RGNX)
www.publicnow.com - May 16 at 7:32 AM
News IconAfter Last Week What Do Analysts Think Of REGENXBIO Inc. (NASDAQ:RGNX) - Share Trading News (NASDAQ:RGNX)
www.sharetrading.news - May 10 at 12:25 PM
News IconEarnings Outlook on Regenxbio Inc (NASDAQ:RGNX) - B.O.D.Y Confidential (NASDAQ:RGNX)
www.bodyconfidential.com - May 7 at 11:39 AM
News IconLatest Analyst Ratings For REGENXBIO Inc. (NASDAQ:RGNX) - Share Trading News (NASDAQ:RGNX)
www.sharetrading.news - May 5 at 12:19 PM
publicnow.com logoREGENXBIO Reports First Quarter 2016 Financial Results and Recent Operational Highlights (NASDAQ:RGNX)
www.publicnow.com - May 5 at 8:21 AM
publicnow.com logoREGENXBIO to Participate in May Investor Conferences (NASDAQ:RGNX)
www.publicnow.com - May 3 at 8:10 AM
kcregister.com logoStocks in News: Paragon Shipping (NASDAQ:PRGN), Regenxbio (NASDAQ:RGNX), 3M Company (NYSE:MMM ... - KC Register (NASDAQ:RGNX)
www.kcregister.com - May 2 at 12:40 PM
thestreet.com logoValeant revamps board, reveals government investigations (NASDAQ:RGNX)
www.thestreet.com - April 29 at 11:44 AM
capitalcube.com logoETF’s with exposure to REGENXBIO, Inc. : April 28, 2016 (NASDAQ:RGNX)
www.capitalcube.com - April 28 at 1:42 PM
thestreet.com logoSurprising Analyst 12-Month Target For IUSG (NASDAQ:RGNX)
www.thestreet.com - April 28 at 11:49 AM
streetinsider.com logoForm 8-K REGENXBIO Inc. For: Apr 19 (NASDAQ:RGNX)
www.streetinsider.com - April 19 at 11:46 AM
publicnow.com logoPreclinical Data from REGENXBIO’s RGX-314 and RGX-121 Gene Therapy Programs to be Presented at the American Society of Gene & Cell Therapy 19th Annual Meeting (NASDAQ:RGNX)
www.publicnow.com - April 19 at 8:25 AM
fxpips.com logoFresh 52-week Lows at the Close – PBYI, VSLR, ORPN, HBHC, DAC, MNDO, LOV (NASDAQ:RGNX)
www.fxpips.com - March 30 at 11:02 AM

Social

Regenxbio (NASDAQ:RGNX) Chart for Friday, September, 30, 2016


Last Updated on 9/30/2016 by MarketBeat.com Staff